Biotech News - Stock Signal | Stock Signal

Stock Signalpowered by ChatGPT

Sign in

Menu

About

Terms & Conditions

Biotech News - Stock Signal | Stock Signal

Aug 6, 11:45 PM

Natera outlines $2.85B-$2.91B 2026 revenue outlook backed by 31% growth ex true-ups

Aug 6, 11:45 PM

Viatris raises 2026 outlook while targeting $500M peak sales for fast-acting meloxicam

Aug 6, 11:45 PM

Trevi outlines 200+ global trial sites as it targets FDA alignment for non-IPF-ILD chronic cough in H2 2026

Aug 6, 11:25 PM

Halozyme projects 2026 non-GAAP EPS of $8.65-$9.00 while raising revenue outlook to $1.835B-$1.91B

Aug 6, 11:15 PM

Pennant anticipates $1.17B-$1.19B 2026 revenue as it raises EPS outlook to $1.34-$1.41

Aug 6, 10:55 PM

GoodRx projects $790M-$805M revenue and $240M-$250M adjusted EBITDA as Pharma Direct targets 70%+ growth

Aug 6, 10:45 PM

Immunocore outlines TEBE-AM data as early as end of 2026 while scaling KIMMTRAK beyond ~1,000 patients per year

Aug 6, 10:26 PM

Establishment Labs signals $269M-$271M 2026 revenue as minimally invasive approaches 15% of sales

Aug 6, 10:25 PM

Novavax expects $235M-$275M in 2026 adjusted total revenue while targeting $150M-$200M in 2028 non-GAAP R&D and SG&A

WELL Health Technologies Non-GAAP EPS of $0.04 misses by $0.02, revenue of $400.43M beats by $13.8M